Oral rifaximin for active microscopic colitis flare
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether an oral antibiotic called rifaximin can improve symptoms during a microscopic colitis flare. It aims to see if it is safe and effective for people whose colitis was confirmed by colon biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have microscopic colitis confirmed by colon biopsy showing collagenous colitis or lymphocytic colitis
- Your diagnosis must have been reviewed and confirmed by two separate pathology experts
- You are currently in an active flare with more than 3 watery or loose stools per day
- Your flare has lasted enough time (at least 4 days out of the last 7, during the past 4 weeks)
- Your symptoms happened within the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication (SAR444336) can help adults with microscopic colitis stay in remission longer. It may be an option if you are already taking budesonide and have had flares in the past 8 months.
This trial tests whether the antibiotic rifaximin can prevent pouchitis from coming back after a first episode. It is for people who had ulcerative colitis, have a J-pouch, and developed pouchitis within the first year after their final surgery.
This study tests whether adding a probiotic supplement to the antibiotic rifaximin improves treatment for people with irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO), a condition where too many bacteria grow in the small intestine. If you have IBS and SIBO, this combination might help reduce your symptoms.
This trial tests a medication called rifaximin (an antibiotic that works in the gut) to see if it reduces bloating in people with functional bowel disorders like IBS or chronic constipation. If you have stubborn bloating despite treatment, this could be a new option to help you feel better.
This trial tests if rifaximin, a gut-targeted antibiotic, can help people with fatty liver disease who also have metabolic problems like obesity or diabetes. You need a recent fatty liver diagnosis and a liver fat level of at least 8% on an MRI scan.
This trial tests whether a combination of two medications—rifaximin (a gut antibiotic) and NAC (a supplement that helps break down mucus)—can reduce belly pain and diarrhea in people with IBS whose symptoms are not well controlled. It may be an option if other treatments haven't worked well enough.
Hear when a new Microscopic Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.